Business Wire

Alkegen Backed by Clearlake Capital, Announces New Aerogel Technology

Share

Alkegen, a leading specialty materials platform creating transformational materials, today introduced its latest proprietary technology, AlkeGel™ by Alkegen. AlkeGel is a next generation flexible aerogel material designed for electric vehicle and battery fire protection applications, along with other industrial thermal management uses. AlkeGel from Alkegen offers exceptionally low thermal conductivity and dustiness, superior thermal performance and a reduction in insulation thicknesses compared to competing insulation products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005730/en/

AlkeGel is Alkegen’s first step into fiber-based aerogel composite materials for critical applications in battery and electric vehicle safety, fire protection and industrial thermal management segments. Alkegen is the new company launched in January following the acquisition of Lydall Materials by Unifrax. Alkegen is a one-of-a-kind specialty materials platform dedicated to human health and sustainability. Alkegen is a global leader in transformative high growth battery technologies, filtration media and specialty insulation with a deep history of vertically integrated manufacturing at large scale to provide solutions for advanced industries including electric vehicles, filtration, aerospace, and chemical processing. The company expects production for AlkeGel materials to come online in mid-2022 with plans to build thousands of tons of long-term manufacturing capacity.

”AlkeGel is the latest development from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Chad Cannan, Senior Vice President and Chief Innovation Officer at Alkegen. “These composite aerogel materials offer excellent insulation properties, and include advanced proprietary technology features we’ve developed with our novel aerogel process. AlkeGel creates performance advantages for our customersin terms of improved product handling, a wide range of shapes and sizes and step change EV fire safety relative to other high performance insulations on the market today. Alkegen’s AlkeGel technology coupled with the broadest set of large scale global end product forming and finishing operations marks a new horizon for these exciting materials,” said Cannan.

“This transformational aerogel portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium ion battery protection, cryogenic applications along with the broader industrial and fire protection markets. AlkeGel products add to our complete portfolio of robust electric vehicle and battery solutions which include AGM separator materials, novel silicon anode materials, lithium ion glass separators, interstitial thermal runaway barriers, and battery compartment fire protection systems,” added John Dandolph, President and CEO of Alkegen.

Alkegen will be available to discuss their innovative new aerogel materials during the 2022 AABC Europe Show June 13, in Mainz, and The Battery Show June 28, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com.

About Alkegen

Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com.

About Clearlake

Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $30 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:

For Alkegen:
Deborah L. Myers
Director, Marketing Communication
dmyers@alkegen.com
716.768.6465

For Clearlake:
Jennifer Hurson
jhurson@lambert.com
845-507-0571

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Announces Additional Leadership for UK and EMEA to Support Continued Growth18.5.2022 17:11:00 CEST | Press release

Align, the premier global provider of technology infrastructure solutions celebrates significant growth throughout the UK and EMEA markets with management changes to support increasing demand. The appointment of Giulia Marcolina as Managing Director and Mike Konold as AV Solutions Director of Align’s UK-based headquarters, will enable the team to deliver innovative collaborative technology and state-of-the-art AV solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005833/en/ Giulia Marcolina, a 15 year veteran with Align, is named Managing Director of Align's UK-based headquarters. (Photo: Business Wire) Giulia brings over 25 years of IT experience, previously serving as Align’s Programme Manager, delivering corporate office relocation and consolidation projects for clients such as Blackrock, Total Gas and Power, and UBS. In her new role, she will lead Align’s team of project managers in building upon Align’s lon

RMS Advances Climate Risk Modeling and Moves More Models to High Definition18.5.2022 16:30:00 CEST | Press release

RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, today announces it will be releasing four new High Definition™ (HD) models, including Europe Windstorm, North America Winterstorm (WT), North America Severe Convective Storm (SCS), and Terrorism. RMS HD Models represent the next generation of risk modeling, delivering deeper analysis and granularity from Moody’s. The HD probabilistic models incorporate a high-fidelity, simulation-based framework for modeling event frequency and severity, to provide a major step forward in the quality of catastrophe risk quantification. The framework allows for event footprints to be represented more realistically across larger event sets. The new RMS Europe Windstorm HD Model further enhances the current model and will cover 17 countries, adding Finland and Lichtenstein. The HD model includes a climate variability view and has expanded storm surge analytics to include the U.K., Ireland, France, and Belgium. Storm c

Suketu Upadhyay Elected to Vertex Board of Directors18.5.2022 16:30:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyayhas been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. “We are delighted to have Suky join the Vertex Board. His extensive financial and strategic experience in health care, paired with his leadership and expertise across biopharma and medtech, make him a valuable addition to our board of directors,” said Reshma Kewalramani, M.D., Vertex’s Chief Executive Officer and President. “It’s an honor to join Vertex, a company focused on serial innovation with an

Armory Makes Continuous Deployment Achievable and Effortless, at any Scale, for all Developers18.5.2022 16:17:00 CEST | Press release

Armory, the Continuous Deployment company empowering development teams to easily, reliably, safely, and continuously deploy software at any scale, today announced public early access to their new Continuous Deployment-as-a-Service product. Armory Continuous Deployment-as-a-Service delivers declarative deployments, across multiple environments, that support advanced strategies, so developers can focus on building great code rather than deploying it. “We believe deploying software continuously, at any scale, should be achievable and effortless for all developers of the world, not just the likes of Google and Netflix,” said Jim Douglas, President and CEO, Armory. “It’s our vision and mission to unlock innovation through software to make software continuous, scalable, secure, and safe, so developers can improve and protect their customers’ experience with confidence and ease.” To effectively compete in a software-defined world, development teams must ensure a stellar customer experience. S

Sermo Survey Reveals New Lung & Breast Cancer Research Rated as Most Interesting by Oncologists Attending ASCO This Year18.5.2022 15:15:00 CEST | Press release

A new survey from Sermo, a physician-first online community and leader in global HCP insights, timed to the annual American Society of Clinical Oncology (ASCO) conference found that nearly half (47%) of attending oncologists are most interested in new data being presented about lung cancer. This is followed by a similarly high interest in new data about breast cancer, as reported by 44% of oncologists surveyed. Additionally, oncologists/hematologists reported they are most excited about learning about tumor targeting antibodies treatments as reported by 54% of those surveyed. Ahead of ASCO’s Annual Meeting, new cancer research and innovations are the driving reason surveyed oncologists/hematologists are attending the conference this year (59%). However, how they plan to attend looks different to many oncologists, as only 18% of oncologists/hematologists surveyed said they will attend ASCO in-person this year. A Look Into the Pandemic’s Negative Impacts on Cancer Care Globally Oncologis

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom